A biosimilar version of the world’s best-selling drug is ‘highly similar’ to the reference product, according to a US Food and Drug Administration staff briefing documents published ahead of tomorrow’s committee meeting.
The documents consider the similarity of ABP 501, a product being developed by US biotech major Amgen (Nasdaq: AMGN), to Humira (adalimumab), a mega-blockbuster arthritis drug marketed by US pharma major AbbVie (NYSE: ABBV).
The FDA’s Arthritis Advisory Committee will take the briefing documents into account as they consider whether Amgen should receive licensure for the indications for which Humira is currently authorized. These include rheumatoid and psoriatic arthritis, adult Crohn’s disease, ulcerative colitis and plaque psoriasis.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze